Right here, we explain a pharmacogenetics strategy that permits to selectively and reversibly inactivate LC neurons making use of Designer Receptors Exclusively Activated by Designer Medicines (DREADD). We show the expression in the hM4Di DREADD can be limited to noradrenergic LC neurons Which the amount of LC inhibition might be adjusted by adapti